process for preparing taxol by the condensation of a (2R, 3S) acid of general formula (I) with a taxan derivative of general formula (II), followed by the removal of the groups R2 and R3 protecting the hydroxy groups and intermediates used therein. ##STR1##

Patent
   RE34277
Priority
Nov 01 1991
Filed
Nov 01 1991
Issued
Jun 08 1993
Expiry
Nov 01 2011
Assg.orig
Entity
Large
42
4
all paid
13. A taxan derivative of the formula: ##STR14## wherein R3 is a trialkylsilyl group in which each portion contains 1 to 3 carbon atoms.
12. A taxan derivative of the formula: ##STR13## wherein R3 is a trialkylsilyl group in which each alkyl portion contains 1 to 3 carbon atoms.
14. A taxan derivative of the formula: ##STR15## wherein R2 is a hydroxy-protecting group and R3 is a trialkylsilyl group in which each portion contains 1 to 3 carbon atoms.
1. A process for preparing taxol of formula: ##STR9## in which a (2R, 3S) 3-phenylisoserine derivative of general formula: ##STR10## in which R2 is a hydroxy-protecting group, is esterified with a taxan derivative of general formula: ##STR11## in which R3 is a hydroxy-protecting group, and the protecting groups R2 and R3 are then both replaced by hydrogen.
16. A process for preparing taxol of the formula: ##STR16## comprising the following steps: A. reacting a compound of the following formula: ##STR17## with a halotrialkylsilane wherein each alkyl portion contains 1 to 3 carbon atoms, to form a compound of the following formula: ##STR18## in which R3 is chosen from trialkylsilyl groups in which each alkyl portion contains 1 to 3 carbon atoms;
B. acetylating the compound so obtained with acetyl chloride to give a compound of the following formula: ##STR19## C. esterifying the compound so obtained with a (2R, 3S) 3-phenylisoserine derivative of the general formula: ##STR20## in which R2 is a hydroxy-protecting group; and D. replacing both of the protecting groups R2 and R3 by hydrogen.
2. A process according to claim 1, in which R2 is chosen from methoxymethyl, 1-ethoxyethyl, benzyloxymethyl, (β-trimethylsilylethoxy)methyl, tetrahydropyranyl and 2,2,2-trichloroethoxycarbonyl, and R3 is chosen from trialkylsilyl groups in which each alkyl portion contains 1 to 3 carbon atoms.
3. A process according to claim 2, in which the esterification is performed in the presence of a condensing agent and an activating agent.
4. A process according to claim 3, in which the condensing agent is chosen from carbodiimides and reactive carbonates, and the activating agent is chosen from dialkylaminopyridines.
5. A process according to claim 4, in which the condensing agent is chosen from dicyclohexylcarbodiimide and di-2-pyridyl carbonate and the activating agent is 4-dimethylaminopyridine.
6. A process according to claim 1, in which the reaction is performed in an aromatic organic solvent chosen from benzene, toluene, xylenes, ethylbenzene, isopropylbenzene and chlorobenzene.
7. A process according to claim 1, in which the reaction is performed at a temperature of between 60° and 90°C
8. A process according to claim 1, in which the replacement of the protecting groups with hydrogen in the intermediate (2'R, 3'S) ester obtained, of general formula: ##STR12## in which R2 and R3 are as defined in claim 1, is performed in an acid medium.
9. A process according to claim 8, in which the acid medium comprises and inorganic acid dissolved in an aliphatic alcohol containing 1 to 3 carbon atoms.
10. A process according to claim 9, in which the inorganic acid is hydrochloric acid.
11. A process according to claim 8, in which the reaction is performed at a temperature in the region of 0°C
15. A taxan derivative according to claim 14 wherein R2 is chosen from methoxymethyl, 1-ethoxyethyl, benzyloxymethyl, (β-trimethylsilylethoxy)methyl, tetrahydropyranyl and 2,2,2-trichloethoxycarbonyl.
17. A process according to claim 16 in which R2 is methoxymethyl, 1-ethoxyethyl, benzyloxymethyl, (β-trimethylsilylethoxy)methyl, tetrahydropyranyl or 2,2,2-trichloroethoxycarbonyl.

The present n relates to a process for preparing taxol from a derivative of 10-deacetylbaccatine III or baccatine.

Among taxan derivatives which correspond to the general formula: ##STR2## taxol is that for which R denotes an acetyl radical and R1 denotes a (2'R,3'S) --OCO--CHOH--CH(C6 H5)--NHCOC6 H5 radical, 10-deacetylbaccatine III is that for which R denotes a hydrogen atom and R1 denotes a hydroxy radical and baccatine III is that for which R denotes an acetyl radical and R1 denotes a hydroxy radical.

Whereas taxol exhibits noteworthy properties in vitro as a promoter of tubulin polymerization and as an inhibitor of tubule depolymerization, and as a result constitutes an especially important antileukaemic and antitumour agent, 10-deacetylbaccatine III and baccatine III do not manifest these activities.

Taxol and baccatine III are extracted with difficulty and in generally low yields, of the order of 100 mg/kg in the case of taxol, from the trunk barks of different Taxus species.

Baccatine III is found in larger amounts in the wood of these different plant species.

In contrast, 10-deacetylbaccatine III is extracted much more readily and in better yields (300 mg/kg of leaves) from yew leaves.

A process enabling taxol to be prepared from 10-deacetylbaccatine III, which is readily accessible and whose production does not necessitate the total destruction of the plant species, is hence especially advantageous.

In European Patent Application EP No. 253,739, the preparation was described of taxol and 10-deacetyltaxol from a taxan derivative of general formula: ##STR3## The preparation of this from baccatine III or from 10-deacetylbaccatine III, forms the subject of European Patent Application EP No. 253,738, and necessitates the intermediate separation of the diastereoisomers. As a result, it is impossible for all the baccatine III or 10-deacetylbaccatine III introduced to yield taxol having the appropriate configuration.

The present invention provides a process for preparing taxol of formula: ##STR4## in which a (2R, 3S) 3-phenylisoserine derivative of general formula: ##STR5## in which R2 is a hydroxy-protecting group, is esterified with a taxan derivative of general formula: ##STR6## in which R3 is a hydroxy-protecting group, and the protecting groups R2 and R3 are then both replaced by hydrogen.

This process may be used to produce taxol in good yield from a starting material which is easily obtained in quantity.

In the general formula (III), R2 denotes, more especially, a methoxymethyl, 1-ethoxyethyl, benzyloxymethyl, (β-trimethylsilylethoxy)methyl, tetrahydropyranyl or 2,2,2-trichloroethoxycarbonyl radical. Preferably, R2 is a 1-ethoxyethyl radical.

In the general formula (IV), R3 denotes, more especially, a trialkylsilyl radical in which each alkyl portion contains 1 to 3 carbon atoms. Preferably, R3 is a trimethylsilyl or triethylsilyl radical It is especially advantageous to use a product of general formula (IV) in which R3 denotes a triethylsilyl radical.

In general, the esterification of the taxan derivative of general formula (IV) with the acid of general formula (III) is performed in the presence of a condensing agent, for example a carbodiimide such as dicyclohexylcarbodiimide or a reactive carbonate such as di-2-pyridyl carbonate, and an activating agent, for example a dialkylaminopyridine such as 4-dimethylaminopyridine, working in an aromatic solvent such as benzene, toluene, a xylene, ethylbenzene, iospropylbenzene or chlorobenzene at a temperature of between 60° and 90°C

In general, an excess of acid of general formula (III) and of condensing agent (dicyclohexylcarbodiimide, di-2-pyridyl carbonate) is used, preferably 6 to 10 moles of each per mole of taxan derivative of general formula (IV), and at least one mole, and preferably 2 to 4 moles, of activating agent (4-dimethylaminopyridine) per mole of taxan derivative of general formula (IV).

The removal of the groups protecting the (2'R,3,S) ester obtained, of general formula: ##STR7## in which R2 and R3 are defined as above, is generally accomplished by treatment in an acid medium. It is especially advantageous to use an acid such as hydrochloric acid, dissolved in an aliphatic alcohol containing 1 to 3 carbon atoms (methanol, ethanol, propanol, isopropanol) at a temperature in the region of 0°C

The product of general formula (III) may be obtained by the saponification of a (2R, 3S) ester of general formula: ##STR8## in which R2 is defined as above and R denotes an alkyl group containing 1 to 4 carbon atoms, and preferably methyl, by means of an inorganic base such as an alkali metal hydroxide (lithium hydroxide, sodium hydroxide) or an alkali metal carbonate or bicarbonate (sodium bicarbonate, potassium carbonate), in an aqueousalcoholic medium such as an ethanol/water or methanol/water mixture, working at a temperature of between 10° and 40°C and preferably in the region of 25°C

The product of general formula (VI) may be obtained under the usual conditions for preparation of ethers, and more especially according to the processes described by J. N. Denis et al., J. Org. Chem., 51, 46-50 (1986).

The product of general formula (IV) may be obtained by the action of a halotrialkylsilane on baccatine III or on 10-deacetylbaccatine III, followed, in the latter case, by the acetylation of the intermediate 7-trialkylsilyl-10-deacetylbaccatine III obtained.

In general, the reaction of the halotrialkylsilane with baccatine III or with 10-deacetylbaccatine III is performed at a temperature in the region of 20°C, working in a basic organic solvent such as pyridine or in an inert organic solvent such as chloroform or dichloroethane in the presence of a tertiary amine such as triethylamine, Hunig's base or pyridine.

The acetylation of the 7-trialkylsilyl-10-deacetylbaccatine III is generally accomplished by means of acetyl chloride, working at a temperature in the region of 0°C in a basic organic solvent such as pyridine or in an inert organic solvent such as methylene chloride, chloroform or dichloroethane in the presence of a tertiary amine such as pyridine or Hunig's base.

The example which follows, given without implied limitation, shows how the invention can be put into practice.

42.8 mg (0.12 mmol) of N-benzoyl-O-(1-ethoxyethyl)-3-phenylisoserine in 1 cm3 of anhydrous toluene are introduced under an argon atmosphere into a 5-cm3 round-bottomed flask equipped with a magnetic stirrer. 25.9 mg (0.12 mmol) of di-2-pyridyl carbonate are then added. The mixture is left to react for 4 to 5 minutes, and 4.9 mg (0.04 mmol) of 4-dimethylaminopyridine and 14 mg (0.02 mmol) of 7-triethylsilylbaccatine III are then added in a single portion. The colourless and homogeneous solution is left for 3 to 4 minutes, and then heated for 10 hours at 72°-74°C After being cooled, the reaction mixture is diluted by adding ethyl acetate. The organic solution is washed 3 times with saturated aqueous sodium bicarbonate solution, twice with water and then twice with saturated sodium chloride solution. The organic phase is dried over anhydrous sodium sulphate. After filtration and removal of the solvents under reduced pressure (20 mm of mercury; 2.7 kPa), the residue obtained is purified by analytical thin-layer chromatography on silica, eluting with an ether/methylene chloride (5:95 by volume) mixture, 4 runs being performed. 8.4 mg (0.0081 mmol) of ester of general formula (V) in which R2 denotes a 1-ethoxyethyl radical and R3 denotes a triethylsilyl radical is thereby obtained, in a 40% yield, in the form of a mixture of 2 epimers in the ratio 60:40, melting at 169°-173°C after recrystallization in a methylene chloride/pentane mixture.

5.8 mg of 7-triethylsilylbaccatine III are recovered. The ester obtained has the following characteristics:

optical rotation: [α]24 =-33.7° (c=0.41; methanol)

infrared spectrum (film): 3450, 3300, 3060, 3025, 2950, 2930, 2900, 2870, 1740, 1720, 1640, 1600, 1580, 1520, 1480, 1450, 1365, 1310, 1260, 1240, 1175, 1140, 1105, 1090, 1080, 1020, 980, 945, 820 and 710 cm-1

proton nuclear magnetic resonance spectrum (300 MHz; deuterated chloroform; chemical shift in ppm; coupling constants J in Hz):

0.53-0.62 (m, 6H); 0.93 (t, J=8, 9H); 1.00 (t, J=7, less abundant epimer 3H); 1.04 (t, J=7, preponderant epimer 3H); 1.18 (preponderant epimer) and 1.19 (less abundant epimer) (2s, 3H); 1.22 (s, 3H); 1.20 and 1.29 (2d, J=5.3, 3H); 1.70 (s, 3H); 1.85-1.95 (m, 1H); 2.00 and 2.01 (2d, J=1.2, 3H); 2.05-2.20 (m, 1H); 2.16 (s, 3H); 2.26-2.40 (m, 1H); 2.40 (preponderant epimer) and 2.53 (less abundant epimer) (2s, 3H); 2.46-2.59 (m, 1H); 3.04-3.44 (m, 2H); 3.81 (preponderant epimer) and 3.83 (less abundant epimer) (2d, J=7, 1H); 4.24 (less abundant epimer) and 4.26 (preponderant epimer) (2ABq, JAB =8.1, δAB =34, 2H); 4.47 (dd, J=6.6 and 10.6, 1H); 4.64 (less abundant epimer) and 4.72 (preponderant epimer) (2d, J=2.7 and 3.7, 1H); 4.54 (less abundant epimer) and 4.80 (preponderant epimer) (2q, J=5.3, 1H); 4.94 (ps.-t, J=6.7 and 7.3, 1H); 5.68-5.76 (m, 2H); 6.24 (ps.-t, J=8 and 9, 1H); 6.44 (s, 1H); 7.08 (less abundant epimer) and 7.18 (preponderant epimer) (2d, J=8.6 and 8.1, 1H); 7.28-7.53 (m, 10H); 7.57-7.63 (m, 1H); 7.77-7.80 (m, 2H); 8.10-8.15 (m, 2H)

mass spectrum (FAB; NBA matrix): m/e=1040 (MH+)

elemental analysis: C57 H73 O15 SiN

______________________________________
elemental analysis: C57 H73 O15 SiN
______________________________________
Calculated % C 65.81 H 7.07 N 1.35
Found 65.57 7.34 1.62
______________________________________

72 mg (0.009 mmol) of the ester obtained above are introduced at 0° C. under an argon atmosphere into a 10-cm3 round-bottomed flask equipped with a magnetic stirrer. 3.6 cm3 of a 0.5% strength ethanolic hydrochloric acid solution, cooled beforehand to 0°C, are added. The mixture is stirred at 0°C for 30 hours. When the reaction is complete, the reaction mixture is diluted by adding ethylacetate at 0°C, and water is then added. After settling has taken place, the separated organic phase is washed 5 times with water and twice with saturated sodium chloride solution and is then dried over anhydrous sodium sulphate. After filtration, the solvents are removed under reduced pressure (20 mm of mercury; 2.6 kPa). The residue obtained (72 mg) is purified by preparative thinlayer chromatography on silica, eluting with a dichloromethane/methanol (90:10 by volume) mixture. 54 mg (0.063 mmol) of taxol are thereby obtained.

The yield is 91%.

The taxol thereby obtained has the following characteristics:

optical rotation: [α]24 =-49.7° (c=0.36; methanol)

infrared spectrum (film): 3400, 3060, 3025, 3000, 2950, 2900, 1740, 1720, 1650, 1600, 1580, 1520, 1480, 1450, 1370, 1315, 1260, 1240, 1180, 1110, 1070, 1030, 980, 950, 905, 800 and 710 cm-1

proton nuclear magnetic resonance spectrum (300 MHz; deuterated chloroform; chemical shifts in ppm; coupling constants in Hz):

1.15 (s, 3H); 1.24 (s, 3H); 1.69 (s, 3H); 1.80 (s, 3H);

1.83 (s, 1H); 1.83-1.93 (m, 1H; 2.24 (s, 3H); 2.28-2.39

(m, 2H); 2.39 (s, 3H); 2.47 (d, J=4, 1H); 2.48-2.57 (m, 1H); 3.55 (d, J=5, 1H); 3.80 (d, J=7, 1H); 4.25 (ABq, JAB =8.4, δAB =32, 2H); 4.37-4.44 (m, 1H); 4.80 (dd, J=2.5 and 5, 1H); 4.95 (d, J=7.7, 1H); 5.68 (d, J=7, 1H); 5.79 (dd, J=2.5 and 8.8, 1H); 6.23 (t, J=9, 1H); 6.27 (s, 1H); 6.98 (d, J=8.8, 1H); 7.33-7.54 (m, 10H); 7.59-7.64 (m, 1H); 7.72-7.75 (m, 2H); 8.12-8.15 (m, 2H)

13 C nuclear magnetic resonance spectrum (deuterated chloroform):

9.57 (CH3); 14.83 (CH3); 20.83 (CH3); 21.62 (CH3); 22.85 (CH3); 26.69 (CH3); 35.65 (CH2); 35.73 (CH2); 43.20 (C); 45.86 (CH); 55.05 (CH); 58.67 (C); 72.20 (CH); 72.41 (CH); 73.23 (CH); 75.00 (CH); 75.58 (CH); 76.58 (CH2); 79.10 (C); 81.21 (C); 84.42 (CH); 127.06 (CH); 128.38 (CH); 128.72 (CH); 129.04 (CH); 129.21 (C); 130.22 (CH); 131.97 (CH); 133.26 (C); 133.71 (CH); 138.03 (C); 141.98 (C); 167.04 (C); 170.37 (C); 171.22 (C); 172.73 (C); 203.62 (C)

mass spectrum (FAB; NBA matrix): m/e=854 (MH+).

(2R, 3S)-N-Benzoyl-O-(1-ethoxyethyl)-3-phenylisoserine may be obtained in the following manner:

380 mg of N-benzoyl-O-(1-ethoxyethyl)-3-phenylisoserine methyl ester are added into a 100 cm3 round-bottomed flask equipped with a magnetic stirrer and containing 30 cm3 of methanol. To the solution obtained, 15 cm3 of distilled water and 414 mg (3 mmol) of solid potassium carbonate are added. The mixture is stirred for 40 hours at 25°C and the methanol is then evaporated off under reduced pressure. The residual aqueous phase is extracted several times with ether. The aqueous phase is acidified with 10% strength (w/v) aqueous hydrochloric acid solution and then extracted with dichloromethane. The combined organic phases are washed several times with water and then with saturated sodium chloride solution. The organic phases are dried over anhydrous magnesium sulphate. After filtration and removal of the solvent under reduced pressure, 254 mg (0.711 mmol) of N-benzoyl-O-(1-ethoxyethyl)-3-phenylisoserine are obtained, the characteristics of which are as follows:

melting point: 93°-94°C

infrared spectrum (film): 3425, 3600-2100, 3060, 3025, 2950, 2925, 1740, 1640, 1600, 1580, 1520, 1480, 1440, 1300, 1140, 1075, 1020, 950, 920, 865, 800, 770 and 700 cm-1

proton nuclear magnetic resonance spectrum (300 MHz; deuterated chloroform; chemical shifts in ppm; coupling constants J in Hz): 0.90 and 1.07 (2t, J=7, 3H); 1.24 (d, J=5.3, 3H); 2.88-2.99 and 3.24-3.45 (2m, 2H); 4.50 and 4.63 (2d, J=2.4, 1H); 4.60 and 4.81 (2q, J=5.3, 1H); 5.74-5.80 (m, 1H); 7.26-7.52 (m, 4H); 7.48-7.83 (m, 2H); 7.0-7.8 (broad s, 1H).

(2R, 3S)-N-Benzoyl-O-(1-ethoxyethyl)-3-phenylisoserine methyl ester may be prepared in the following manner:

2.99 mg (1 mmol) of N-benzoyl-3-phenylisoserine methyl ester, 10 cm3 of dry dichloromethane, 25.1 mg (0.1 mmol) of pyridinium p-toluenesulphonate and 956.4 μl (721 mg; 10 mmol) of ethyl vinyl ether are introduced successively into a 25-cm3 round-bottomed flask equipped with a magnetic stirrer. The reaction mixture is stirred for 3 hours at 25°C When the reaction is complete, 1 drop of pyridine is added and the reaction mixture is then diluted by adding dichloromethane. The organic phase is washed twice with water and then with saturated sodium chloride solution, and dried over anhydrous sodium sulphate. After filtration and removal of the solvents under reduced pressure, 380 mg of N-benzoyl-O-(1-ethoxy- ethyl)-3-phenylisoserine methyl ester are obtained in the form of an equimolecular mixture of 2 epimers, the characteristics of which are as follows:

melting point: 124°-125°C (after recrystallization in a dichloromethane/pentane mixture)

optical rotation: [α]23 =-25.9° (c=0.54; methanol)

infrared spectrum (film): 3350, 3060, 3025, 2980, 2940, 1740, 1635, 1600, 1580, 1530, 1490, 1435, 1380, 1340, 1320, 1275, 1242, 1198, 1175, 1150, 1080, 1030, 990, 955, 900, 800, 702 and 698 cm-1

proton nuclear magnetic resonance spectrum (300 MHz; deuterated chloroform; chemical shifts in ppm; coupling constants J in Hz):

0.87 and 0.98 (2t, J=7, 3H); 1.13 and 1.22 (2d, J=5.4, 3H); 2.82 and 2.89 and 3.22-3.36 (m, 2H); 3.755 and 3.76 (2s, 3H); 4.48 and 4.60 (2d, J=2.4, 1H); 4.50 and 4.78 (2q, J=5.4, 1H); 5.64 and 5.68 (2dd, J=2.4 and

8.2, 1H); 7.18 and 7.19 (2d, J=8.2, 1H); 7.23-7.55 (m, 8H); 7.80-7.84 (m, 2H)

mass spectrum (FAB, NBA matrix): m/e=372 (MH+)

elemental analysis: C21 H25 O5 N

______________________________________
elemental analysis: C21 H25 O5 N
______________________________________
Calculated % C 67.90 H 6.78 N 3.77
Found 67.98 6.94 3.75
______________________________________

N-Benzoyl-3-phenylisoserine methyl ester may be prepared according to J. N. Denis et al., J. Org. Chem., 51. 46-50 (1986).

7-Triethylsilylbaccatine III may be repeated in one of the following ways:

(a) 544 mg (1 mmol) of 10-deacetylbaccatine III, dissolved in 50 cm3 of anhydrous pyridine, are introduced under an argon atmosphere into a 100-cm3 round-bottomed flask equipped with a magnetic stirrer. 3.36 cm3 (3.014 g; 20 mmol) of triethylsilyl chloride are then added. The homogeneous, yellow reaction mixture is then stirred for 24 hours at 0°C Ethyl acetate and water are then added. After settling has taken place, the separated aqueous phase is extracted with ethyl acetate. The combined organic phases are treated with saturated aqueous copper sulphate solution until the pyridine has been completely removed. The organic phases are washed with water and then with saturated sodium chloride solution, and then dried over anhydrous sodium sulphate. After filtration and evaporation of the solvents under reduced pressure, 2.73 g of a product are obtained, and this is purified on a silica column, eluting with a dichloromethane/methanol (99:1 by volume) mixture. 512 mg (0.778 mmol) of 10-deacetyl-7-triethylsilylbaccatine III are thereby obtained, in a 78% yield, in the form of a white solid, the characteristics of which are as follows:

melting point: 256°-257°C (after recrystallization in a dichloromethane/pentane mixture)

optical rotation: [α]23 =-23.6° (c=0.41; methanol)

infrared spectrum (film): 3450, 2950, 2875, 1735, 1705, 1600, 1580, 1450, 1380, 1275, 1242, 1180, 1140, 1115, 1100, 1075, 1060, 1030, 1020, 1000, 990, 950, 925, 885, 860, 822, 740 and 715 cm-1

proton nuclear magnetic resonance spectrum (300 MHz; deuterated chloroform; chemical shifts in ppm; coupling constants J in Hz):

0.48-0.70 (m, 6H); 0.94 (t, J=8, 9H); 1.08 (s, 6H); 1.57 (s, 1H); 1.74 (s, 3H); 1.86-1.95 (m, 1H); 2.02 (d, J=5, 1H); 2.09 (d, J=1.1, 3H); 2.25-2.35 (m, 2H); 2.28 (s, 3H); 2.42-2.52 (m, 1H); 3.95 (d, J=7, 1H); 4.24 (ABq, JAB =8.2, δAB =42, 2H); 4.24 (d, J=2, 1H); 4.41 (dd, J=6.6 and 10.6, 1H); 4.85-4.90 (m, 1H); 4.95 (dd, J=1.9 and 9.6, 1H); 5.17 (d, J=2, 1H); 5.60 (d, L, J=7, 1H); 7.44-7.50 (m, 2H); 7.57-7.62 (m, 1H); 8.08-8.11 (m, 2H)

13 C nuclear magnetic resonance spectrum (deuterated chloroform):

5.16 (CH2); 6.72 (CH3); 9.92 (CH3); 15.13 (CH3); 19.50 (CH3); 22.60 (CH3); 26.86 (CH3); 37.26 (CH2); 38.64 (CH2); 42.70 (C); 46.99 (CH); 57.96 (C); 67.95 (CH); 72.95 (CH); 74.68 (CH); 74.83 (CH); 76.57 (CH2); 78.78 (C); 80.75 (C); 84.25 (CH); 128.57 (CH); 129.44 (C); 130.07 (CH); 133.57 (CH); 135.20 (C); 141.78 (C); 167.04 (C); 170.76 (C); 210.31 (C)

mass spectrum (FAB; NBA matrix): m/e=659 (MH)

elemental analysis: C35 H50 O10 Si

______________________________________
elemental analysis: C35 H50 O10 Si
______________________________________
Calculated % C 63.80 H 7.65 Si 4.26
Found 63.57 7.72 4.04
______________________________________

43.9 mg (0.075 mmol) of 10-deacetyl-7-triethylsilylbaccatine III, dissolved in 1.87 cm3 of anhydrous pyridine, are introduced under an argon atmosphere into a 10-cm3 round-bottomed flask equipped with a magnetic stirrer. The solution is cooled to 0°C and 26.6 μl (29.4 mg; 0.375 mmol) of acetyl chloride are then added dropwise. The mixture, which becomes heterogeneous, is stirred for 20 hours at 0° C. A further 26.6 μl of acetyl chloride are added and the mixture is then stirred for 20 hours at 0°C Ethyl acetate is added, followed by water, at 0°C After settling has taken place, the separated aqueous phase is extracted twice with ethyl acetate. The combined organic phases are washed with saturated aqueous copper sulphate solution until the pyridine has been completely removed, then with water and then with saturated sodium chloride solution, and are finally dried over anhydrous sodium sulphate. After filtration and removal of the solvents under reduced pressure, the residue obtained (65 mg) is purified by chromatography on a silica gel column, eluting with a dichloromethane/methanol (99:1 by volume) mixture. 45 mg (0.0643 mmol) of 7-triethylsilylbaccatine III are thereby obtained in an 86% yield, the characteristics of which are as follows:

melting point: 253°-254°C (after recrystallization in a dichloromethane/pentane mixture)

optical rotation: [α]23 =-48.6° (c=0.36; methanol)

infrared spectrum (film): 3500, 2950, 2875, 1720, 1600, 1580, 1450, 1370, 1270, 1240, 1180, 1140, 1110, 1100, 1075, 1050, 1020, 990, 970, 950, 820 740 and 710 cm-1

proton nuclear magnetic resonance spectrum (300 MHz; deuterated chloroform; chemical shifts in ppm; coupling constants J in Hz):

0.52-0.65 (m, 6H); 0.93 (t, J=8, 9H); 1.05 (s, 3H); 1.20 (s, 3H); 1.61 (s, 1H); 1.68 (s, 3H); 1.83-1.92 (m, 1H); 2.01 (d, J=5, 1H); 2.17 (s, 3H); 2.19 (d, J=1.1, 3H); 2.24-2.28 (m, 2H); 2.28 (s, 3H); 2.41-2.58 (m, 1H); 3.88 (d, J=7, 1H); 4.23 (ABq, JAb =8.1, δAB =45, 2H); 4.45 (dd, J=6.6 and 10.5, 1H); 4.83 (m, 1H); 4.96 (d, J=9.6, 1H); 5.63 (d, J=7, 1H); 6.46 (s, 1H); 7.45-7.50 (m, 2H); 7.57-7.63 (m, 1H); 8.09-8.12 (m, 2H)

13 C nuclear magnetic resonance spectrum (deuterated chloroform): 5.28, 6.72; 9.93; 14.93; 20.06; 20.93; 22.68; 26.83; 37.24; 38.24; 42.79; 47.24; 58.67; 68.00; 72.35; 74.35; 75.77; 76.57; 78.73; 80.89; 84.22; 128.57; 129.38; 130.09; 132.78; 133.61; 143.83; 167.12; 169.33; 170.76 and 202.12

mass spectrum (FAB; NBA matrix): m/e=701 (MH+)

elemental analysis: C37 H52 O11 Si

______________________________________
elemental analysis: C37 H52 O11 Si
______________________________________
Calculated % C 63.40 N 7.48 Si 4.01
Found 63.50 7.59 3.94
______________________________________

(b) 250 mg (0.4266 mmol) of baccatine III, dissolved in 8.5 cm3 of anhydrous pyridine, are introduced under an argon atmosphere into a 25 cm3 round-bottomed flask equipped with a magnetic stirrer. 1.43 cm3 (1.286 g; 8.53 mmol) of triethylsilyl chloride are then added. The mixture is stirred for 28 hours at 20°C Ethyl acetate is added, followed by water. After settling has occurred, the aqueous phase is extracted with ethyl acetate, the combined organic phases are washed with saturated aqueous copper sulphate solution until the pyridine has been completely removed, then with water and finally with saturated aqueous sodium chloride solution. The organic phases are dried over anhydrous sodium sulphate. After filtration and evaporation of the solvents under reduced pressure, a residue (1.35 g) is obtained, and this is purified by filtration on a silica gel column, eluting with dichloromethane/methanol (99:1 by volume) mixture. 248 mg (0.354 mmol) of 7-triethylsilyl baccatine III are thereby obtained, in an 83% yield, in the form of a white solid, melting at 253°-254°C after recrystallization in a dichloromethane/pentane mixture.

Denis, Jean-Noel, Guenard, Daniel, Greene, Andrew E., Gueritte-Voegelein, Francoise

Patent Priority Assignee Title
5380916, Nov 04 1901 University of Florida Method for the isolation and purification of taxane derivatives
5405972, Jul 20 1993 Florida State University Synthetic process for the preparation of taxol and other tricyclic and tetracyclic taxanes
5445809, Mar 03 1992 Montana State University Production of taxol from the yew tree
5451392, Mar 03 1992 Montana State University Production of taxol
5618952, Jul 20 1993 Florida State University Synthetic process for the preparation of tricyclic and tetracyclic taxanes
5637732, Jul 20 1993 Florida State University Tricyclic and tetracyclic taxanes
5670673, Nov 02 1990 University of Florida Method for the isolation and purification of taxol and its natural analogues
5688977, Feb 29 1996 Tapestry Pharmaceuticals, Inc Method for docetaxel synthesis
5717103, Oct 05 1992 AVENTIS PHARMA S A Process for the esterification of baccatin III and of 10-deacetylbaccatin III
5750737, Sep 25 1996 MAYNE PHARMA USA , INC Method for paclitaxel synthesis
5760251, Jan 19 1996 SEPRACOR, INC Taxol process and compounds
5760252, Jul 20 1993 Florida State University Synthetic process for the preparation of tricyclic and tetracyclic taxanes
5811550, Nov 20 1992 AVENTIS PHARMA S A Process for the preparation of a 1,3-oxazolidine-5-carboxylic acid
5907042, Nov 21 1997 Indena S.p.A. Intermediates and methods useful in the semisynthesis of paclitaxel and analogs
5917062, Nov 21 1997 Indena S.p.A; INDENA S P A Intermediates and methods useful in the semisynthesis of paclitaxel and analogs
5977375, Oct 05 1992 AVENTIS PHARMA S A Esters of baccatin III and 10-deacetylbaccatin III
6005120, Jul 20 1993 Florida State University Tricyclic and tetracyclic taxanes
6025516, Oct 14 1998 CHIRAGENE, INC Resolution of 2-hydroxy-3-amino-3-phenylpropionamide and its conversion to C-13 sidechain of taxanes
6107497, Feb 29 1996 Tapestry Pharmaceuticals, Inc Intermediate for use in docetaxel synthesis and production method therefor
6111144, Aug 21 1997 Florida State University Method for the synthesis of a taxane intermediate
6133462, Sep 25 1996 MAYNE PHARMA USA , INC C-7 CBZ baccatin III and production method therefor
6184395, May 17 1999 Bristol-Myers Squibb Company Reaction conditions for the cleavage of silyl ethers in the preparation of paclitaxel(taxol®) and paclitaxel analogues
6191287, Apr 09 1998 Florida State University Process for selective derivatization of taxanes
6222053, Oct 18 1996 CHATHAM BIOTEC LTD Semi-synthesis of a protected baccatin III compound
6242614, May 28 1999 Bristol-Myers Squibb Company Semi-synthesis of paclitaxel using dialkyldichlorosilanes
6248908, Aug 11 1999 Bristol-Myers Squibb Company Process for the preparation of a paclitaxel C-4 methyl carbonate analog
6278026, Jul 20 1993 Florida State University Intermediates for tricyclic or tetracyclic taxanes
6291691, Aug 18 1997 Florida State University Process for selective derivatization of taxanes
6353120, Aug 11 1999 Bristol-Myers Squibb Company Process for the preparation of a paclitaxel C-4 methyl carbonate analog
6410756, Oct 24 1996 Institut National de la Recherche Scientifique Family of Canadensol taxanes, the semi-synthetic preparation and therapeutic use thereof
6433189, Jul 20 1993 Florida State University Tricyclic and tetracyclic taxane intermediates
6441253, Aug 21 1997 Florida State University Method for the synthesis of taxanes
6452025, Apr 25 2001 MAYNE PHARMA USA , INC Three-step conversion of protected taxane ester to paclitaxel
6479679, Apr 25 2001 MAYNE PHARMA USA , INC Two-step conversion of protected taxane ester to paclitaxel
6500966, Mar 02 1999 Indena S.p.A. Process for the preparation of taxanes from 10-deacetylbaccatin III
6576777, Oct 18 1996 CHATHAM BIOTEC LTD Semi-synthesis of a protected baccatin III compound
6630609, Aug 21 1997 Florida State University Taxane synthesis method and intermediates
6706896, Aug 18 1997 Florida State University Process for selective derivatization of taxanes
6861537, Jul 20 1993 Florida State University Tricyclic and tetracyclic taxane intermediates
7202370, Oct 27 2003 CONOR MEDSYSTEMS, INC Semi-synthesis of taxane intermediates from 9-dihydro-13-acetylbaccatin III
7288665, Apr 20 1998 UNIVERSITY, FLORIDA STATE Process for selective derivatization of taxanes
RE40120, Feb 23 2000 Indena S.p.A. Process for the preparation of taxanes from 10-deacetylbaccatin III
Patent Priority Assignee Title
4814470, Jul 17 1986 AVENTIS PHARMA S A Taxol derivatives, their preparation and pharmaceutical compositions containing them
4857653, Jul 17 1986 AVENTIS PHARMA S A Process for the preparation of taxol and 10-deacetyltaxol
EP253738,
EP253739,
///
Executed onAssignorAssigneeConveyanceFrameReelDoc
Nov 01 1991Centre National de la Recherche Scientifique(assignment on the face of the patent)
Jun 28 1995Centre National de la Recherche ScientifiqueRHONE-POULENC RORER S A ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0075620600 pdf
Dec 20 1999RHONE-POULENC RORER S A AVENTIS PHARMA S A CHANGE OF NAME SEE DOCUMENT FOR DETAILS 0115060357 pdf
Date Maintenance Fee Events
Oct 28 1993M183: Payment of Maintenance Fee, 4th Year, Large Entity.
Nov 08 1993ASPN: Payor Number Assigned.
Sep 30 1997M184: Payment of Maintenance Fee, 8th Year, Large Entity.
Oct 22 1997ASPN: Payor Number Assigned.
Oct 22 1997RMPN: Payer Number De-assigned.
Nov 01 2001M185: Payment of Maintenance Fee, 12th Year, Large Entity.


Date Maintenance Schedule
Jun 08 19964 years fee payment window open
Dec 08 19966 months grace period start (w surcharge)
Jun 08 1997patent expiry (for year 4)
Jun 08 19992 years to revive unintentionally abandoned end. (for year 4)
Jun 08 20008 years fee payment window open
Dec 08 20006 months grace period start (w surcharge)
Jun 08 2001patent expiry (for year 8)
Jun 08 20032 years to revive unintentionally abandoned end. (for year 8)
Jun 08 200412 years fee payment window open
Dec 08 20046 months grace period start (w surcharge)
Jun 08 2005patent expiry (for year 12)
Jun 08 20072 years to revive unintentionally abandoned end. (for year 12)